SLE (SYSTEMIC LUPUS)
Clinical trials for SLE (SYSTEMIC LUPUS) explained in plain language.
Never miss a new study
Get alerted when new SLE (SYSTEMIC LUPUS) trials appear
Sign up with your email to follow new studies for SLE (SYSTEMIC LUPUS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Gene-Edited immune cells take on lupus and scleroderma in first human test
Disease control Recruiting nowThis early-stage study is testing a one-time treatment called CTX112, made from donor immune cells edited with CRISPR technology. It aims to see if it is safe and can help adults with severe lupus, scleroderma, or myositis that haven't improved with standard treatments. About 80 …
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
New drug hopes to calm lupus skin flares
Disease control Recruiting nowThis study tests an experimental drug called VENT-03 in 24 adults with active lupus skin disease (cutaneous lupus), with or without systemic lupus. For the first 4 weeks, some get the drug and some get a placebo; then everyone gets VENT-03 for 8 more weeks. The goal is to see if …
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE2 • Sponsor: Ventus Therapeutics U.S., Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Immune cell therapy takes on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-phase study tests a new treatment using a patient's own immune cells, modified to target and attack harmful immune cells causing autoimmune diseases like lupus and scleroderma. About 20 adults aged 18 to 70 will receive CD19 or CD19-BCMA CAR-T cells. The main goal is t…
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC